Search Results

You are looking at 171 - 180 of 1,415 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Barriers to the Use of Breast Cancer Risk Reduction Therapies

Arvind Bambhroliya, Mariana Chavez-MacGregor, and Abenaa M. Brewster

Breast Cancer Prevention Trial (BCPT) enrolled women based on either age of 60 years or older, or age 35 to 59 years with a modified Gail model 5-year predicted risk of breast cancer of 1.66% or greater or a history of lobular carcinoma in situ (LCIS

Full access

BIO24-031: Hierarchical Multimodal Learning on Pan-Squamous Cell Carcinomas for Improved Survival Outcomes

Asim Waqas, Aakash Tripathi, Ashwin Mukund, Paul Stewart, Mia Naeini, and Ghulam Rasool

using pan-Squamous Cell Carcinomas (SCC) in the head and neck (HNSC), bladder (BLCA), lung (LUSC), cervical (CESC), and esophageal (ESCA) cancers having 476; 399; 355; 291; and 154 patients, respectively. We fine-tune and validate our approach for lung

Full access

BPI24-018: Quality Recommendations for the Management of Cutaneous Squamous Cell Carcinoma (CSCC)

Eva Muñoz, Javier Cañueto Álvarez, Josep Oriol Bermejo Segú, Almudena García Castaño, Vanessa Gabriela Jerviz Guía, Ana María López López, Susana Puig Sardá, Onofre Sanmartín Jiménez, Ainara Soria Rivas, Paula Gratal, Teresa Pardo, Alvaro Rogado, and Alfonso Berrocal

context. Currently, managing cutaneous squamous cell carcinoma (CSCC) requires a multidisciplinary approach due to its complexity, but Spain lacks consensus on some aspects of its diagnosis and treatment. Methods: A Working Group composed of 10

Full access

Multiple Approvals, Celestial Prices, Unimproved Outcomes: The Tale of Cost-Ineffective Drugs in Hepatocellular Carcinoma

Bishal Gyawali

Hepatocellular carcinoma (HCC) is one of the most lethal cancers. In the United States, the 5-year survival rate is only 18%, and rates for advanced or metastatic disease are much poorer, at around 2%. 1 In 2007, sorafenib became the first targeted

Full access

Optimizing Treatment for Head and Neck Cancers: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Presented by: Robert I. Haddad

combination with chemotherapy as new first-line standard-of-care therapies for patients with recurrent/metastatic HNC squamous cell carcinoma (HNSCC). “You are now required to get a combined positive score [CPS] on your patient,” reported Dr. Haddad at the

Full access

Successful Imatinib Therapy for Neuroendocrine Carcinoma With Activating KIT Mutation: A Case Study

James Perkins, Patrick Boland, Steven J. Cohen, Anthony J. Olszanski, Yan Zhou, Paul Engstrom, and Igor Astsaturov

diarrhea. A CT scan revealed an enlarged liver extending to the pelvis with numerous hypodense metastatic foci without evidence of a primary tumor ( Figure 1A ). Fine-needle aspiration (FNA) biopsy of the liver demonstrated neuroendocrine carcinoma with

Full access

PCL22-186: A Potential Biomarker for Radiosensitivity of Squamous Cell Carcinomas in the Head and Neck

Lourdes Bernardino, Payton Kooiker,, Juan Cintron-Garcia, Crystal Boudreaux, and Roni Bollag

Background : Patients with squamous cell carcinoma in the head and neck often undergo radiation treatment with unwanted side effects and tumor recurrence. A biomarker that will predict response to radiotherapy will benefit these patients. Many

Full access

The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions

Toni K. Choueiri and Robert J. Motzer

Targeted therapies have changed the landscape of metastatic renal cell carcinoma (mRCC), with a current median survival of approximately 30 months reported in contemporary trials, representing a drastic improvement over the 12- to 13-month overall

Full access

HSR20-079: Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study

En Cheng, Peiyin Hung, and Shi-Yi Wang

Background: Transplantation, surgical resection, radiofrequency ablation, and percutaneous ethanol injection are generally considered as potentially curative treatments for patients of hepatocellular carcinoma (HCC). With the increasing incidence

Full access

Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study

Sarah Asad, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce Niland, Antonio C. Wolff, Michael J. Hassett, and Daniel G. Stover

stage at diagnosis compared with those who did not have rrTNBC ( supplemental eTable 2 ). Figure 1. CONSORT diagram. Abbreviations: DCIS, ductal carcinoma in situ; HER2+, HER2-positive; HR+, hormone receptor–positive; LCIS, lobular carcinoma in situ